Durvalumab + Gem/Cis for cholangiocarcinoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 13 Mar 2020: Trial registered, NCT04308174
  2. 20 May 2020: Trial started, NCT04308174

The trials

NCT04308174: Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer

State
Under way
Phase
Phase 2
People
45 taking part
Started
20 May 2020
Primary completion
30 Jun 2023
Arms
Durvalumab + Gem/Cis
Results
None posted
  1. 13 Mar 2020: Trial registered
  2. 20 May 2020: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.